The Journal of Experimental Medicine
VeriKine-HS Human IFN-Beta
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 163K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ugolini, S.
Right arrow Articles by Sattentau, Q. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ugolini, S.
Right arrow Articles by Sattentau, Q. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
© The Rockefeller University Press, 0022-1007/1997/10/1287/ $5.00
The Journal of Experimental Medicine, Volume 186, Number 8, October 20, 1997 1287-1298

Articles

Inhibition of Virus Attachment to CD4+ Target Cells Is a Major Mechanism of T Cell Line–adapted HIV-1 Neutralization

Sophie Ugolini*, Isabelle Mondor*, Paul W.H.I. Parren{ddagger}, Dennis R. Burton{ddagger}, Shermaine A. Tilley§, Per Johan Klasse, and Quentin J. Sattentau*

From the * Centre d'Immunologie de Marseille-Luminy, 13288 Marseille, France; {ddagger} The Scripps Research Institute, La Jolla, CA, 92037; § Public Health Research Institute, New York 10016; and Medical Research Council Laboratory for Molecular Cell Biology, University College London, London WCIE 6BT, UK

Antibody-mediated neutralization of human immunodeficiency virus type–1 (HIV-1) is thought to function by at least two distinct mechanisms: inhibition of virus–receptor binding, and interference with events after binding, such as virus–cell membrane fusion. Here we show, by the use of a novel virus–cell binding assay, that soluble CD4 and monoclonal antibodies to all confirmed glycoprotein (gp)120 neutralizing epitopes, including the CD4 binding site and the V2 and V3 loops, inhibit the adsorption of two T cell line–adapted HIV-1 viruses to CD4+ cells. A correlation between the inhibition of virus binding and virus neutralization was observed for soluble CD4 and all anti-gp120 antibodies, indicating that this is a major mechanism of HIV neutralization. By contrast, antibodies specific for regions of gp120 other than the CD4 binding site showed little or no inhibition of either soluble gp120 binding to CD4+ cells or soluble CD4 binding to HIV-infected cells, implying that this effect is specific to the virion–cell interaction. However, inhibition of HIV-1 attachment to cells is not a universal mechanism of neutralization, since an anti-gp41 antibody did not inhibit virus–cell binding at neutralizing concentrations, implying activity after virus–cell binding.

Address correspondence to Dr. Q.J. Sattentau, Centre d'Immunologie de Marseille Luminy, 163 Avenue de Luminy, Case 906, 13288 Marseille Cedex 9, France. Phone: 33-4-91-26-94-94; FAX: 33-4-91-26-94-30; E-mail: sattenta{at}ciml.univ-mrs.fr

1 Abbreviations used in this paper: bs, binding site; GM, growth medium; gp, glycoprotein; i, induced; s, soluble; TCLA, T cell line adapted; WB, wash buffer.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS